Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 3Active not recruiting 3Completed 2Withdrawn 1Terminated 1Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Gynecologic 1

Conditions

Melanoma 2Uveal Melanoma 1Skin Neoplasms 1Melanoma, Cutaneous Malignant 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × lifileucel × Dermatologic × Clear all
NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT05607095 2026-05-28

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
30 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Iovance Biotherapeutics, Inc.

Phase 3 Recruiting
670 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡